Bemfola® can potentially reduce drug wastage and associated costs of Infertility treatment

///Bemfola® can potentially reduce drug wastage and associated costs of Infertility treatment
Bemfola® can potentially reduce drug wastage and associated costs of Infertility treatment2019-01-18T09:18:28+00:00

Project Description

Bemfola, an EMA approved biosimilar of Gonal-f, is a recombinant folliclestimulating hormone (rFSH) used for in-vitro fertilisation (IVF). Having demonstrated equivalent efficacy and safety to Gonal-f, Bemfola is approved for identical indications as Gonal-f and as such, is also a viable alternative to urinary derived FSH, Menopur.

NICE guidance (CG-156) concludes that there is no difference in clinical effectiveness between urinary and recombinant FSH products, and therefore recommends the use of either type of product. However, available products do differ in terms of their delivery device and available strengths; Gonal-f is provided as a multidose pen, Menopur in vials or multidose preparation, and Bemfola as a fixed dose pen.

The aim of this study was to determine the impact of delivery device on drug wastage and associated cost.

Read our findings here…. (Bemfola can potenitally reduce)